IL17A and osteoporosis: The results of KEGG and GO functional enrichment suggest that curculigoside may treat osteoporosis by inhibiting the overproduction of osteoclastic cytokines and their induction of oxidative damage, primarily through modulation of the Rap1, IL-17, HIF-1, and TNF signaling pathways.